SOME BELIEVE THAT LIQUID BIOPSY TECHNOLOGY has the potential to develop into a Holy Grail of cancer diagnostics. Yet progress in this field has been slow. Now a recent lab acquisition may accelerate the development of clinically-useful liquid biopsies. There is keen interest in how to achieve the noninvasive diagnosis of cancer. Investors have ploughed […]
- Genomics Update
NeoGenomics Acquires Inivata to Access Liquid Biopsy Technology
FDA gave Inivata’s RaDaR technology designation as a ‘breakthrough device’
- By Robert Michel
- > From the Volume XXVIII, No. 12 - September 7, 2021 Issue
